Lynn Hopkins of Ohio is happy she went with her gut and continued to explore her health issues, because it eventually led her ...

The FDA has accepted for priority review a new supplemental biologics license application for Winrevair to treat adults with ...

Pulmonary arterial hypertension (PAH) is a rare, progressive disorder impacting small pulmonary arteries, leading to increased vascular resistance and heart failure. The latest report forecasts ...

Panelists discuss how the future of PAH treatment looks promising with potential for disease remission through reverse remodeling agents, emphasizing the need for continued research focus on patients ...

There is increased risk for pulmonary hypertension in patients with both atrial fibrillation and incident venous thromboembolism.

Researchers determined the presence of pulmonary hypertension was associated with worse outcomes for patients with polycythemia vera.